Great Novel Therapeutics Biotech & Medicals
TWO: 7427.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Chia-Nan Chen
- Employees
- 18
- Headquarters
- Taipei City, Taiwan
- IPO year
- 2021
- Market cap
- NT$1.8B
- Website
- https://www.gntbm.com.tw
Loading 7427…
Loading profile data…Frequently asked questions about 7427
What does Great Novel Therapeutics Biotech & Medicals (7427.TWO) do?
Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers. It develops drugs for cancer immunotherapy, including tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was formerly known as GNT Biotech &...
Where does 7427.TWO trade?
Great Novel Therapeutics Biotech & Medicals (7427.TWO) trades on the Taipei Exchange.
What sector is 7427.TWO in?
Great Novel Therapeutics Biotech & Medicals (7427.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Great Novel Therapeutics Biotech & Medicals?
Chia-Nan Chen is the chief executive officer of Great Novel Therapeutics Biotech & Medicals (7427.TWO).
Where is Great Novel Therapeutics Biotech & Medicals headquartered?
Great Novel Therapeutics Biotech & Medicals is headquartered in Taiwan.
Does 7427.TWO pay a dividend?
Great Novel Therapeutics Biotech & Medicals (7427.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 7427.TWO go public?
Great Novel Therapeutics Biotech & Medicals (7427.TWO) completed its initial public offering in 2021.